Counterpoint Mutual Funds LLC Makes New Investment in CVS Health Corporation $CVS

Counterpoint Mutual Funds LLC bought a new position in shares of CVS Health Corporation (NYSE:CVS) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,941 shares of the pharmacy operator’s stock, valued at approximately $570,000.

A number of other large investors have also recently made changes to their positions in CVS. TOWER TRUST & INVESTMENT Co increased its position in CVS Health by 0.8% during the fourth quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock worth $1,247,000 after buying an additional 132 shares during the period. CYBER HORNET ETFs LLC boosted its holdings in shares of CVS Health by 4.1% in the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock valued at $259,000 after acquiring an additional 134 shares during the period. LS Investment Advisors LLC grew its position in shares of CVS Health by 3.9% during the fourth quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock worth $284,000 after acquiring an additional 135 shares during the last quarter. Moss Adams Wealth Advisors LLC increased its holdings in shares of CVS Health by 4.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock valued at $239,000 after acquiring an additional 135 shares during the period. Finally, Northwestern Mutual Investment Management Company LLC increased its holdings in shares of CVS Health by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock valued at $3,219,000 after acquiring an additional 136 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at CVS Health

In related news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 3,441,551 shares of company stock worth $323,703,977. Company insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on CVS. Wall Street Zen cut shares of CVS Health from a “buy” rating to a “hold” rating in a research note on Monday, June 29th. TD Cowen lifted their price objective on shares of CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Barclays upped their target price on shares of CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a report on Tuesday, May 26th. Weiss Ratings reiterated a “hold (c)” rating on shares of CVS Health in a research note on Friday, May 8th. Finally, Bank of America boosted their price target on CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Twenty-one equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $101.28.

CVS Health Stock Performance

NYSE:CVS opened at $104.74 on Friday. The firm’s fifty day moving average price is $94.56 and its 200 day moving average price is $83.29. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $106.15. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a market cap of $133.64 billion, a price-to-earnings ratio of 46.14, a price-to-earnings-growth ratio of 1.03 and a beta of 0.61.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter in the prior year, the firm earned $2.25 EPS. CVS Health’s quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts expect that CVS Health Corporation will post 7.44 EPS for the current year.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.